NasdaqGS:ILMN
NasdaqGS:ILMNLife Sciences

Why Illumina (ILMN) Is Up 5.9% After CMS Backs TruSight Oncology Comprehensive Reimbursement

Earlier in January 2026, Illumina announced that the Centers for Medicare and Medicaid Services granted reimbursement for its FDA-approved TruSight Oncology Comprehensive in vitro diagnostic test, setting a US$2,989.55 Clinical Laboratory Fee Schedule rate under PLA code 0543U. This decision creates a clear reimbursement pathway that could accelerate adoption of comprehensive genomic profiling in everyday oncology practice, particularly across community and regional laboratories that...
NasdaqGS:RGLD
NasdaqGS:RGLDMetals and Mining

Royal Gold (RGLD) Valuation Check After Tenth Straight Dividend Raise And Record Gold Prices

Royal Gold (RGLD) has attracted investors’ attention after announcing a 6% dividend increase for 2026, its 10th straight annual raise, at a time when gold prices sit at record highs. See our latest analysis for Royal Gold. The dividend news arrives during a strong run in the stock, with a 30 day share price return of 20.66% and a 90 day share price return of 52.41%. The 1 year total shareholder return of 103.52% signals powerful momentum for investors who have stayed the course. If Royal...
NYSE:FUN
NYSE:FUNHospitality

Six Flags (FUN) Taps High-Coupon Debt: Smart Balance-Sheet Move or Costly Capital Allocation Shift?

In mid-January 2026, Six Flags Entertainment closed a private offering of US$1.00 billion in 8.625% senior notes due 2032 to redeem its lower-coupon 2027 notes and pay associated interest. This refinancing extends the company’s debt maturity profile while highlighting ongoing debates over its capital allocation priorities amid activist investor pressure on its balance sheet and real estate. With this sizeable high-coupon refinancing reshaping Six Flags’ liabilities, we’ll now examine how...
NasdaqGS:ANAB
NasdaqGS:ANABBiotechs

Assessing AnaptysBio (ANAB) Valuation As Technical Strength Meets Improving Profitability Prospects

Technical momentum meets improving fundamentals Recent analysis flags AnaptysBio (ANAB) as fitting the Minervini Trend Template while also pointing to earnings growth and a move toward profitability. This mix has started to draw more focused investor attention. See our latest analysis for AnaptysBio. The recent pullback, with a 7.1% 7 day share price return and 7.3% 30 day share price return, follows a strong 37.3% 90 day share price return and a very large 1 year total shareholder return of...
NasdaqGS:ARWR
NasdaqGS:ARWRBiotechs

Is Arrowhead Pharmaceuticals (ARWR) Fairly Priced After Strong 1 Year Share Price Surge?

If you are wondering whether Arrowhead Pharmaceuticals' current share price offers good value, this article will walk through what the numbers are saying about the stock. The share price is at US$67.60, with returns of 2.6% over the last 7 days, a 2.0% decline over 30 days, a 0.3% decline year to date, a 243.0% gain over 1 year, a 105.0% gain over 3 years, and a 12.0% decline over 5 years. Recent price moves sit against a backdrop of continuing interest in the company, with investors...
NasdaqGS:PLTR
NasdaqGS:PLTRSoftware

Palantir Expands AI Infrastructure Role As Valuation Stays Under Scrutiny

Palantir Technologies (NasdaqGS:PLTR) has been selected as a key partner for Sovereign AI’s next-generation sovereign-grade AI data center infrastructure rollout across EMEA. The company is also expanding its largest partnership in Korea into a group-wide alliance with HD Hyundai. These moves broaden Palantir’s commercial and government AI infrastructure presence across Europe, the Middle East, Africa, and South Korea. Palantir, best known for its data integration and AI platforms for...
NasdaqGS:AGNC
NasdaqGS:AGNCMortgage REITs

Does AGNC (AGNC) Pairing a 2026 Dividend With a Board Return Refine Its Risk Playbook?

Earlier in January, AGNC Investment Corp. declared a US$0.12 per‑share cash dividend for January 2026 and reappointed economist Dr. Morris Davis to its Board as an independent director on the Compensation and Corporate Governance Committee. His return to the Board, following his recent service on the Council of Economic Advisors as Chief Housing Economist, brings specialized housing and macro policy insight directly into AGNC’s governance framework. We’ll now examine how Dr. Davis’s return...
NYSE:SNOW
NYSE:SNOWIT

Snowflake (SNOW) Valuation Check As Revenue Growth Meets Losses And Rich Price To Sales Multiple

Snowflake stock snapshot after recent performance Snowflake (SNOW) has seen its share price move only slightly over the past week, with a small positive 1 day return and modest 7 day gain, compared with weaker moves over the past month and past 3 months. At a last close of US$206.50, the company reports annual revenue of US$4.39b alongside a net loss of US$1.35b. This gives investors a mix of strong top line scale and ongoing profitability questions to weigh. See our latest analysis for...
NYSE:RVLV
NYSE:RVLVSpecialty Retail

Revolve Opens Grove Flagship As Valuation Questions Linger For Investors

Revolve Group (NYSE:RVLV) has opened a new flagship store at The Grove in Los Angeles. The store introduces a retail concept that blends premium and luxury fashion with experiential design. The location features in house and emerging brands, a dedicated men's section, and authenticated pre owned luxury goods. The concept includes sustainability initiatives with a focus on circular fashion. For investors watching NYSE:RVLV, this move adds a fresh physical touchpoint in one of Los Angeles'...
NasdaqGS:CTBI
NasdaqGS:CTBIBanks

Community Trust Bancorp (CTBI) EPS Jump Reinforces Bullish Profitability Narrative

Community Trust Bancorp (CTBI) just wrapped up FY 2025 with fourth quarter revenue of US$71.8 million and EPS of US$1.51, capping a twelve month stretch that delivered total revenue of US$270.2 million and EPS of US$5.44. Over the past few quarters, revenue has moved from US$60.0 million in Q3 2024 to US$71.8 million in Q4 2025, while quarterly EPS has shifted from US$1.23 to US$1.51, setting up a year where net income reached US$98.1 million on a trailing basis. With net margins running in...
NYSE:GRMN
NYSE:GRMNConsumer Durables

Garmin (GRMN) Valuation Check After New Golf Marine And Outdoor Product Launches

Garmin (GRMN) is in focus after unveiling a slate of new devices across golf, marine and outdoor categories, including the Approach G82, youth focused Approach J1, Xero L60i and quatix 8 Pro. See our latest analysis for Garmin. Despite the flurry of new product launches, Garmin's recent 90 day share price return of an 18.23% decline contrasts with a modest 1.05% share price gain year to date, while the 3 year total shareholder return of 120.37% and 5 year total shareholder return of 94.34%...
NYSE:FLR
NYSE:FLRConstruction

Assessing Fluor (FLR) Valuation After New Rare Earth Project Role In Texas

Fluor’s new rare earth role in Texas Fluor (FLR) has been selected by USA Rare Earth as an engineering, procurement and construction management partner for the Round Top Rare Earth Project in Texas, putting the company into focus for investors tracking critical minerals exposure. See our latest analysis for Fluor. Fluor’s selection for the Round Top project comes after it recently reached mechanical completion on BASF’s large Zhanjiang Verbund site, and the share price has shown mixed...
NYSE:U
NYSE:USoftware

How Unity’s Coda Partnership Shapes the Next Chapter of Unity Software’s (U) Platform Strategy

In January 2026, Coda announced it had integrated Unity’s In-App Purchasing SDK with Coda’s global web store platforms, enabling developers to manage and optimize their digital catalogs across mobile, web, and PC through Unity’s existing workflow. By embedding Coda’s Merchant of Record solution into Unity’s tools, the partnership aims to simplify global payments, compliance, and fraud management so developers can run first-party web stores at scale with fewer operational hurdles. We’ll now...
NYSE:ARES
NYSE:ARESCapital Markets

Assessing Ares Management (ARES) Valuation After Mixed Recent Share Performance

Why Ares Management (ARES) Is On Investors’ Radar Today Ares Management (ARES) is drawing attention after recent share performance, with a decline over the past month but a gain across the past 3 months. This mixed performance is prompting closer inspection of its fundamentals. The alternative asset manager reports revenue of US$5,355.6m and net income of US$511.8m. These figures provide investors with concrete data to consider alongside recent short term share price movements. See our latest...
NYSE:MSCI
NYSE:MSCICapital Markets

Is MSCI (MSCI) Pricing Reflect Its Role In Indexes After Recent Share Weakness

If you are wondering whether MSCI's current share price lines up with what you are actually getting as an investor, this article is designed to help you assess that value question clearly. MSCI shares last closed at US$588.97, with returns of a 1% decline over the past 7 days, 2.1% over 30 days, 4.2% year to date, a 2.7% decline over 1 year, 19.9% over 3 years and 57.6% over 5 years. Recent news around MSCI has focused on its role as a provider of indexes and analytics that many institutions...
NYSE:OWL
NYSE:OWLCapital Markets

Blue Owl Capital Lawsuits Put Liquidity Disclosures And Valuation In Focus

Multiple securities class action lawsuits have been filed against Blue Owl Capital Inc. (NYSE:OWL) over alleged failures to disclose liquidity pressures and asset redemption limits at its business development companies. Plaintiffs also claim company leadership made materially misleading statements about Blue Owl Capital’s financial health and risk profile. The cases raise questions about the firm’s disclosure practices and corporate governance, with potential implications for current and...
NYSE:ABT
NYSE:ABTMedical Equipment

Abbott Broadens Cardiology And Oncology Reach As Valuation Questions Persist

Abbott Laboratories (NYSE:ABT) received CE Mark approval for its TactiFlex Duo ablation catheter for atrial fibrillation in Europe. The company is expanding further into pulsed field ablation with this dual mode catheter for heart rhythm management. Abbott also announced an acquisition of Exact Sciences to enter the cancer diagnostics market. Abbott shares last closed at $120.73, with a 1 year return of 4.4% and a 3 year return of 15.4%. The company is already a large player in medical...
NasdaqGS:CRWV
NasdaqGS:CRWVIT

CoreWeave Lawsuit Puts Capacity Claims And Backlog Conversion In Spotlight

CoreWeave (NasdaqGS:CRWV) faces a material class action lawsuit alleging it misled investors about its operational capacity and supplier risk. The complaint focuses on disclosures tied to CoreWeave's reliance on a single third party data center supplier and its ability to meet AI infrastructure demand. The lawsuit follows a revenue guidance reduction, termination of a major merger, and delays in data center development. CoreWeave runs GPU focused cloud infrastructure for AI workloads, a...
NYSE:LH
NYSE:LHHealthcare

Expanded MRD Test Suite and Dividend Hike Might Change The Case For Investing In Labcorp (LH)

In January 2026, Labcorp Holdings Inc. expanded its molecular residual disease (MRD) testing portfolio with new Plasma Detect ID and Plasma Detect Genome assays for earlier detection of cancer recurrence, while its Board approved a US$0.72 per-share cash dividend payable on March 12, 2026, to shareholders of record on February 27, 2026. The broadened MRD offering, supported by clinical studies across several tumor types, strengthens Labcorp’s role in precision oncology and personalized...
NasdaqGS:CVBF
NasdaqGS:CVBFBanks

CVB Financial (CVBF) Is Up 7.8% After Earnings Rise And Buyback Completion What's Changed

CVB Financial Corp. has reported its fourth-quarter and full-year 2025 results, with net interest income rising to US$122.66 million for the quarter and US$460.29 million for the year, alongside net income of US$55.04 million and US$209.3 million, respectively, compared with the prior year. The company also completed a share repurchase program announced in November 2024, buying back 4,321,777 shares for US$80.4 million, which can influence earnings per share and capital allocation...
NasdaqGM:AAOI
NasdaqGM:AAOICommunications

Why Applied Optoelectronics (AAOI) Is Up 11.3% After Securing A Major 800G AI Data Center Deal

Applied Optoelectronics recently secured its first major volume order for 800G data center transceivers from a hyperscale customer and introduced a new 400-milliwatt narrow-linewidth pump laser aimed at AI data center applications, marking a significant expansion of its product footprint. Together, the volume order and laser launch highlight how the company is aligning its technology roadmap with rapidly rising AI data center infrastructure needs. We’ll now examine how the new 800G...
NasdaqGS:AMAT
NasdaqGS:AMATSemiconductor

Is It Too Late To Consider Applied Materials (AMAT) After 72% One Year Rally?

If you are wondering whether Applied Materials at around US$325.24 is still reasonably priced or starting to look stretched, the next sections will walk through what the current share price might be implying. The stock has recently recorded returns of 1.9% over 7 days, 25.0% over 30 days, 21.0% year to date and 72.3% over 1 year, with 3 year and 5 year returns of 189.1% and 235.8% respectively. This has many investors asking what is already baked into the price. Alongside this share price...
NYSE:CRCL
NYSE:CRCLSoftware

Circle Bermuda Partnership Tests Fully On Chain Economy And CRCL Sentiment

Circle Internet Group partnered with the government of Bermuda to support what is being described as the world's first fully on chain national economy. The collaboration focuses on integrating stablecoins and blockchain infrastructure across Bermuda's financial system. The move positions Circle at the center of a high profile public private experiment in digital assets and national level finance. For investors tracking NYSE:CRCL, this Bermuda partnership comes at a time when the stock is...